nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0967	0.234	CbGbCtD
Dabrafenib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0683	0.165	CbGbCtD
Dabrafenib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0461	0.111	CbGbCtD
Dabrafenib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.044	0.106	CbGbCtD
Dabrafenib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0392	0.0948	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0384	0.0928	CbGbCtD
Dabrafenib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0363	0.0877	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.023	0.0556	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0217	0.0525	CbGbCtD
Dabrafenib—NEK11—lung—chronic obstructive pulmonary disease	0.00594	0.141	CbGeAlD
Dabrafenib—SIK1—respiratory system—chronic obstructive pulmonary disease	0.00414	0.0981	CbGeAlD
Dabrafenib—SIK1—connective tissue—chronic obstructive pulmonary disease	0.00365	0.0863	CbGeAlD
Dabrafenib—SIK1—bronchus—chronic obstructive pulmonary disease	0.00341	0.0807	CbGeAlD
Dabrafenib—RAF1—respiratory system—chronic obstructive pulmonary disease	0.0033	0.0781	CbGeAlD
Dabrafenib—RAF1—connective tissue—chronic obstructive pulmonary disease	0.0029	0.0687	CbGeAlD
Dabrafenib—RAF1—bronchus—chronic obstructive pulmonary disease	0.00271	0.0643	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00266	0.0629	CbGeAlD
Dabrafenib—BRAF—lung—chronic obstructive pulmonary disease	0.00263	0.0622	CbGeAlD
Dabrafenib—RAF1—trachea—chronic obstructive pulmonary disease	0.00244	0.0577	CbGeAlD
Dabrafenib—SLCO1B3—lung—chronic obstructive pulmonary disease	0.00227	0.0536	CbGeAlD
Dabrafenib—SIK1—lung—chronic obstructive pulmonary disease	0.0022	0.0521	CbGeAlD
Dabrafenib—RAF1—lung—chronic obstructive pulmonary disease	0.00175	0.0415	CbGeAlD
Dabrafenib—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000964	0.00288	CcSEcCtD
Dabrafenib—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000964	0.00288	CcSEcCtD
Dabrafenib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000961	0.00287	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000957	0.00286	CcSEcCtD
Dabrafenib—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000948	0.00283	CcSEcCtD
Dabrafenib—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000948	0.00283	CcSEcCtD
Dabrafenib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000946	0.00282	CcSEcCtD
Dabrafenib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000946	0.00282	CcSEcCtD
Dabrafenib—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000942	0.00281	CcSEcCtD
Dabrafenib—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000937	0.0028	CcSEcCtD
Dabrafenib—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000937	0.0028	CcSEcCtD
Dabrafenib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000934	0.00279	CcSEcCtD
Dabrafenib—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000928	0.00277	CcSEcCtD
Dabrafenib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000926	0.00277	CcSEcCtD
Dabrafenib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000926	0.00277	CcSEcCtD
Dabrafenib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000925	0.00276	CcSEcCtD
Dabrafenib—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000924	0.00276	CcSEcCtD
Dabrafenib—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00092	0.00275	CcSEcCtD
Dabrafenib—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000919	0.00274	CcSEcCtD
Dabrafenib—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000919	0.00274	CcSEcCtD
Dabrafenib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000918	0.00274	CcSEcCtD
Dabrafenib—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000915	0.00273	CcSEcCtD
Dabrafenib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000913	0.00273	CcSEcCtD
Dabrafenib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000913	0.00273	CcSEcCtD
Dabrafenib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000906	0.0027	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.000906	0.0027	CcSEcCtD
Dabrafenib—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.0009	0.00269	CcSEcCtD
Dabrafenib—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000899	0.00268	CcSEcCtD
Dabrafenib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000897	0.00268	CcSEcCtD
Dabrafenib—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000895	0.00267	CcSEcCtD
Dabrafenib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000893	0.00267	CcSEcCtD
Dabrafenib—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000889	0.00265	CcSEcCtD
Dabrafenib—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000886	0.00265	CcSEcCtD
Dabrafenib—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000885	0.00264	CcSEcCtD
Dabrafenib—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000884	0.00264	CcSEcCtD
Dabrafenib—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000884	0.00264	CcSEcCtD
Dabrafenib—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000878	0.00262	CcSEcCtD
Dabrafenib—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000878	0.00262	CcSEcCtD
Dabrafenib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000872	0.0026	CcSEcCtD
Dabrafenib—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000868	0.00259	CcSEcCtD
Dabrafenib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000862	0.00258	CcSEcCtD
Dabrafenib—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00086	0.00257	CcSEcCtD
Dabrafenib—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.000859	0.00257	CcSEcCtD
Dabrafenib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000851	0.00254	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000842	0.00251	CcSEcCtD
Dabrafenib—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000835	0.00249	CcSEcCtD
Dabrafenib—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000834	0.00249	CcSEcCtD
Dabrafenib—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000829	0.00248	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000801	0.00239	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000797	0.00238	CcSEcCtD
Dabrafenib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000797	0.00238	CcSEcCtD
Dabrafenib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000797	0.00238	CcSEcCtD
Dabrafenib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00079	0.00236	CcSEcCtD
Dabrafenib—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000789	0.00235	CcSEcCtD
Dabrafenib—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000789	0.00235	CcSEcCtD
Dabrafenib—Cough—Montelukast—chronic obstructive pulmonary disease	0.000781	0.00233	CcSEcCtD
Dabrafenib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000778	0.00232	CcSEcCtD
Dabrafenib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000778	0.00232	CcSEcCtD
Dabrafenib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000778	0.00232	CcSEcCtD
Dabrafenib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000778	0.00232	CcSEcCtD
Dabrafenib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000774	0.00231	CcSEcCtD
Dabrafenib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000774	0.00231	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000772	0.00231	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000772	0.00231	CcSEcCtD
Dabrafenib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000762	0.00227	CcSEcCtD
Dabrafenib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000762	0.00227	CcSEcCtD
Dabrafenib—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000761	0.00227	CcSEcCtD
Dabrafenib—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000761	0.00227	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000756	0.00226	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000755	0.00226	CcSEcCtD
Dabrafenib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000753	0.00225	CcSEcCtD
Dabrafenib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000753	0.00225	CcSEcCtD
Dabrafenib—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000745	0.00223	CcSEcCtD
Dabrafenib—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000745	0.00223	CcSEcCtD
Dabrafenib—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000745	0.00222	CcSEcCtD
Dabrafenib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000741	0.00221	CcSEcCtD
Dabrafenib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000741	0.00221	CcSEcCtD
Dabrafenib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000734	0.00219	CcSEcCtD
Dabrafenib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000734	0.00219	CcSEcCtD
Dabrafenib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000731	0.00218	CcSEcCtD
Dabrafenib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000731	0.00218	CcSEcCtD
Dabrafenib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00073	0.00218	CcSEcCtD
Dabrafenib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00073	0.00218	CcSEcCtD
Dabrafenib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000725	0.00217	CcSEcCtD
Dabrafenib—ABCG2—lung—chronic obstructive pulmonary disease	0.000724	0.0171	CbGeAlD
Dabrafenib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000724	0.00216	CcSEcCtD
Dabrafenib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000724	0.00216	CcSEcCtD
Dabrafenib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000722	0.00215	CcSEcCtD
Dabrafenib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000718	0.00214	CcSEcCtD
Dabrafenib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000716	0.00214	CcSEcCtD
Dabrafenib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000715	0.00213	CcSEcCtD
Dabrafenib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000709	0.00212	CcSEcCtD
Dabrafenib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000704	0.0021	CcSEcCtD
Dabrafenib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000699	0.00209	CcSEcCtD
Dabrafenib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000697	0.00208	CcSEcCtD
Dabrafenib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000697	0.00208	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000696	0.00208	CcSEcCtD
Dabrafenib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000693	0.00207	CcSEcCtD
Dabrafenib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00069	0.00206	CcSEcCtD
Dabrafenib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000684	0.00204	CcSEcCtD
Dabrafenib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000681	0.00203	CcSEcCtD
Dabrafenib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00068	0.00203	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000679	0.00203	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000679	0.00203	CcSEcCtD
Dabrafenib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000674	0.00201	CcSEcCtD
Dabrafenib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000674	0.00201	CcSEcCtD
Dabrafenib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000673	0.0159	CbGeAlD
Dabrafenib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00067	0.002	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000665	0.00199	CcSEcCtD
Dabrafenib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00066	0.00197	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000658	0.00197	CcSEcCtD
Dabrafenib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000658	0.00196	CcSEcCtD
Dabrafenib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000654	0.00195	CcSEcCtD
Dabrafenib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000648	0.00193	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000644	0.00192	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000644	0.00192	CcSEcCtD
Dabrafenib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.00192	CcSEcCtD
Dabrafenib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000643	0.00192	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000641	0.00191	CcSEcCtD
Dabrafenib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000637	0.0019	CcSEcCtD
Dabrafenib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000637	0.0019	CcSEcCtD
Dabrafenib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000637	0.0019	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00063	0.00188	CcSEcCtD
Dabrafenib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00063	0.00188	CcSEcCtD
Dabrafenib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000623	0.00186	CcSEcCtD
Dabrafenib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000618	0.00184	CcSEcCtD
Dabrafenib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000617	0.00184	CcSEcCtD
Dabrafenib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000614	0.00183	CcSEcCtD
Dabrafenib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000612	0.00183	CcSEcCtD
Dabrafenib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000611	0.00182	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00061	0.00182	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00061	0.00182	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000608	0.00181	CcSEcCtD
Dabrafenib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000607	0.00181	CcSEcCtD
Dabrafenib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000602	0.0018	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000597	0.00178	CcSEcCtD
Dabrafenib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000589	0.00176	CcSEcCtD
Dabrafenib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000589	0.00176	CcSEcCtD
Dabrafenib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000589	0.00176	CcSEcCtD
Dabrafenib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000589	0.00176	CcSEcCtD
Dabrafenib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000587	0.00175	CcSEcCtD
Dabrafenib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000582	0.00174	CcSEcCtD
Dabrafenib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000582	0.00174	CcSEcCtD
Dabrafenib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000582	0.00174	CcSEcCtD
Dabrafenib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000579	0.00173	CcSEcCtD
Dabrafenib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000577	0.00172	CcSEcCtD
Dabrafenib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000577	0.00172	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000576	0.00172	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000571	0.00171	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000568	0.0017	CcSEcCtD
Dabrafenib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000556	0.00166	CcSEcCtD
Dabrafenib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000556	0.00166	CcSEcCtD
Dabrafenib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000549	0.00164	CcSEcCtD
Dabrafenib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000549	0.00164	CcSEcCtD
Dabrafenib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000549	0.00164	CcSEcCtD
Dabrafenib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000547	0.00163	CcSEcCtD
Dabrafenib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000543	0.00162	CcSEcCtD
Dabrafenib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000538	0.00161	CcSEcCtD
Dabrafenib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000535	0.0016	CcSEcCtD
Dabrafenib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000535	0.0016	CcSEcCtD
Dabrafenib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000527	0.00157	CcSEcCtD
Dabrafenib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000527	0.00157	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000526	0.00157	CcSEcCtD
Dabrafenib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000524	0.00156	CcSEcCtD
Dabrafenib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000519	0.00155	CcSEcCtD
Dabrafenib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000517	0.00154	CcSEcCtD
Dabrafenib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00051	0.00152	CcSEcCtD
Dabrafenib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00051	0.00152	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000508	0.00152	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000506	0.00151	CcSEcCtD
Dabrafenib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000505	0.00151	CcSEcCtD
Dabrafenib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.0005	0.00149	CcSEcCtD
Dabrafenib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000498	0.00149	CcSEcCtD
Dabrafenib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000497	0.0118	CbGeAlD
Dabrafenib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000495	0.00148	CcSEcCtD
Dabrafenib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000493	0.00147	CcSEcCtD
Dabrafenib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000493	0.00147	CcSEcCtD
Dabrafenib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000483	0.00144	CcSEcCtD
Dabrafenib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000482	0.00144	CcSEcCtD
Dabrafenib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000482	0.00144	CcSEcCtD
Dabrafenib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000474	0.00142	CcSEcCtD
Dabrafenib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000474	0.00142	CcSEcCtD
Dabrafenib—Rash—Formoterol—chronic obstructive pulmonary disease	0.00047	0.0014	CcSEcCtD
Dabrafenib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00047	0.0014	CcSEcCtD
Dabrafenib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00047	0.0014	CcSEcCtD
Dabrafenib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00047	0.0014	CcSEcCtD
Dabrafenib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000467	0.00139	CcSEcCtD
Dabrafenib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000467	0.00139	CcSEcCtD
Dabrafenib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000466	0.00139	CcSEcCtD
Dabrafenib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000465	0.00139	CcSEcCtD
Dabrafenib—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000465	0.00139	CcSEcCtD
Dabrafenib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000464	0.00139	CcSEcCtD
Dabrafenib—Rash—Montelukast—chronic obstructive pulmonary disease	0.00046	0.00137	CcSEcCtD
Dabrafenib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00046	0.00137	CcSEcCtD
Dabrafenib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000457	0.00137	CcSEcCtD
Dabrafenib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000448	0.00134	CcSEcCtD
Dabrafenib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000444	0.00133	CcSEcCtD
Dabrafenib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000443	0.00132	CcSEcCtD
Dabrafenib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000443	0.00132	CcSEcCtD
Dabrafenib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000443	0.00132	CcSEcCtD
Dabrafenib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000441	0.00132	CcSEcCtD
Dabrafenib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000434	0.00129	CcSEcCtD
Dabrafenib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000427	0.00128	CcSEcCtD
Dabrafenib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000418	0.00125	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000415	0.00124	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000413	0.00123	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000406	0.00121	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000404	0.00121	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00039	0.00117	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000386	0.00115	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000375	0.00112	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000373	0.00111	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000369	0.0011	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000365	0.00109	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000365	0.00109	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000362	0.00108	CcSEcCtD
Dabrafenib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000359	0.00107	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000359	0.00107	CcSEcCtD
Dabrafenib—ABCB1—lung—chronic obstructive pulmonary disease	0.000357	0.00846	CbGeAlD
Dabrafenib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000339	0.00101	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000332	0.000992	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00031	0.000927	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000306	0.000914	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000306	0.000914	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000304	0.000907	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000297	0.000888	CcSEcCtD
Dabrafenib—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000293	0.000876	CcSEcCtD
Dabrafenib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000291	0.00087	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000288	0.000859	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000285	0.000851	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000284	0.000847	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000267	0.000798	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000267	0.000797	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000265	0.000792	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000255	0.000761	CcSEcCtD
Dabrafenib—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000255	0.00076	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.000759	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000755	CcSEcCtD
Dabrafenib—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.000755	CcSEcCtD
Dabrafenib—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000749	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00024	0.000716	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00024	0.000716	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000232	0.000692	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000232	0.000692	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000216	0.000645	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000628	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000208	0.00062	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000201	0.000599	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000579	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000557	CcSEcCtD
Dabrafenib—Rash—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000552	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000552	CcSEcCtD
Dabrafenib—Headache—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000549	CcSEcCtD
Dabrafenib—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000174	0.00052	CcSEcCtD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—chronic obstructive pulmonary disease	0.000102	0.000486	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000101	0.000484	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.000101	0.000483	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000101	0.000481	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.89e-05	0.000472	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	9.72e-05	0.000465	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	9.69e-05	0.000463	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	9.69e-05	0.000463	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	9.69e-05	0.000463	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	9.68e-05	0.000463	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HDAC2—chronic obstructive pulmonary disease	9.66e-05	0.000462	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—chronic obstructive pulmonary disease	9.62e-05	0.00046	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	9.6e-05	0.000459	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	9.54e-05	0.000456	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	9.53e-05	0.000456	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	9.52e-05	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	9.48e-05	0.000453	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—chronic obstructive pulmonary disease	9.47e-05	0.000453	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.4e-05	0.000449	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.34e-05	0.000446	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	9.3e-05	0.000444	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.28e-05	0.000443	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	9.25e-05	0.000442	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GCLC—chronic obstructive pulmonary disease	9.23e-05	0.000441	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	9.16e-05	0.000438	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	9.16e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	9.12e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	9.02e-05	0.000431	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KL—chronic obstructive pulmonary disease	8.98e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	8.94e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	8.93e-05	0.000427	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	8.92e-05	0.000426	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MMP1—chronic obstructive pulmonary disease	8.9e-05	0.000425	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	8.89e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—chronic obstructive pulmonary disease	8.81e-05	0.000421	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—LEP—chronic obstructive pulmonary disease	8.78e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PLAU—chronic obstructive pulmonary disease	8.73e-05	0.000417	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	8.68e-05	0.000415	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	8.66e-05	0.000414	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.61e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	8.58e-05	0.00041	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	8.55e-05	0.000408	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.51e-05	0.000406	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	8.48e-05	0.000405	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.48e-05	0.000405	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CTGF—chronic obstructive pulmonary disease	8.42e-05	0.000402	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	8.41e-05	0.000402	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.36e-05	0.0004	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—chronic obstructive pulmonary disease	8.32e-05	0.000398	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	8.32e-05	0.000397	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	8.3e-05	0.000396	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	8.29e-05	0.000396	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	8.27e-05	0.000395	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.18e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	8.03e-05	0.000384	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS2—chronic obstructive pulmonary disease	8.02e-05	0.000383	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	7.99e-05	0.000382	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	7.95e-05	0.00038	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.94e-05	0.00038	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—chronic obstructive pulmonary disease	7.92e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—chronic obstructive pulmonary disease	7.92e-05	0.000378	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.84e-05	0.000375	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.76e-05	0.000371	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.74e-05	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	7.65e-05	0.000366	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—chronic obstructive pulmonary disease	7.59e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	7.45e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—chronic obstructive pulmonary disease	7.45e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	7.45e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—chronic obstructive pulmonary disease	7.39e-05	0.000353	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	7.38e-05	0.000353	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—chronic obstructive pulmonary disease	7.33e-05	0.00035	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	7.31e-05	0.00035	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	7.3e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	7.28e-05	0.000348	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.24e-05	0.000346	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.21e-05	0.000344	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR2—chronic obstructive pulmonary disease	7.16e-05	0.000342	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.11e-05	0.00034	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.83e-05	0.000326	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.8e-05	0.000325	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.78e-05	0.000324	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.77e-05	0.000323	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	6.76e-05	0.000323	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—chronic obstructive pulmonary disease	6.74e-05	0.000322	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.74e-05	0.000322	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB3—chronic obstructive pulmonary disease	6.73e-05	0.000322	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KL—chronic obstructive pulmonary disease	6.73e-05	0.000322	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	6.73e-05	0.000321	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HDAC2—chronic obstructive pulmonary disease	6.68e-05	0.000319	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—chronic obstructive pulmonary disease	6.64e-05	0.000317	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	6.6e-05	0.000315	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	6.6e-05	0.000315	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	6.6e-05	0.000315	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.47e-05	0.000309	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS3—chronic obstructive pulmonary disease	6.45e-05	0.000308	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.4e-05	0.000306	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.38e-05	0.000305	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	6.37e-05	0.000305	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—chronic obstructive pulmonary disease	6.34e-05	0.000303	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.29e-05	0.000301	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.27e-05	0.0003	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KL—chronic obstructive pulmonary disease	6.21e-05	0.000297	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	6.2e-05	0.000296	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.14e-05	0.000293	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	6.08e-05	0.00029	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.04e-05	0.000289	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—chronic obstructive pulmonary disease	5.97e-05	0.000285	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.95e-05	0.000284	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.91e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.84e-05	0.000279	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.81e-05	0.000278	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.8e-05	0.000277	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.78e-05	0.000276	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	5.75e-05	0.000275	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.74e-05	0.000274	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.66e-05	0.00027	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.64e-05	0.000269	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—chronic obstructive pulmonary disease	5.61e-05	0.000268	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.5e-05	0.000263	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	5.5e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—chronic obstructive pulmonary disease	5.43e-05	0.000259	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.35e-05	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.31e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	5.28e-05	0.000252	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.24e-05	0.00025	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.21e-05	0.000249	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.19e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	5.16e-05	0.000247	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.09e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—chronic obstructive pulmonary disease	5.07e-05	0.000242	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB3—chronic obstructive pulmonary disease	5.05e-05	0.000241	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.89e-05	0.000234	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—chronic obstructive pulmonary disease	4.87e-05	0.000233	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.83e-05	0.000231	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	4.78e-05	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	4.74e-05	0.000226	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SERPINE1—chronic obstructive pulmonary disease	4.73e-05	0.000226	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.71e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.68e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB3—chronic obstructive pulmonary disease	4.66e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—chronic obstructive pulmonary disease	4.65e-05	0.000222	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—chronic obstructive pulmonary disease	4.61e-05	0.00022	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—chronic obstructive pulmonary disease	4.59e-05	0.000219	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.58e-05	0.000219	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.54e-05	0.000217	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—chronic obstructive pulmonary disease	4.51e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—chronic obstructive pulmonary disease	4.42e-05	0.000211	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	4.39e-05	0.00021	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.35e-05	0.000208	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.35e-05	0.000208	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	4.35e-05	0.000208	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	4.3e-05	0.000205	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.29e-05	0.000205	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—chronic obstructive pulmonary disease	4.27e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	4.26e-05	0.000204	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.22e-05	0.000202	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	4.09e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—chronic obstructive pulmonary disease	4.06e-05	0.000194	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.03e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.02e-05	0.000192	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4e-05	0.000191	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.97e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—chronic obstructive pulmonary disease	3.88e-05	0.000186	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—chronic obstructive pulmonary disease	3.83e-05	0.000183	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.79e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	3.76e-05	0.00018	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.7e-05	0.000177	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—chronic obstructive pulmonary disease	3.67e-05	0.000175	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.64e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	3.62e-05	0.000173	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.61e-05	0.000172	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.61e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.59e-05	0.000171	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	3.56e-05	0.00017	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	3.54e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—chronic obstructive pulmonary disease	3.51e-05	0.000168	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.51e-05	0.000168	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.32e-05	0.000159	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.31e-05	0.000158	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.29e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.28e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—chronic obstructive pulmonary disease	3.28e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—chronic obstructive pulmonary disease	3.27e-05	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.26e-05	0.000156	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	3.25e-05	0.000155	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.16e-05	0.000151	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.14e-05	0.00015	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.14e-05	0.00015	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—chronic obstructive pulmonary disease	3.12e-05	0.000149	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	3.1e-05	0.000148	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3e-05	0.000143	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—chronic obstructive pulmonary disease	2.98e-05	0.000143	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—chronic obstructive pulmonary disease	2.93e-05	0.00014	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.92e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.89e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—chronic obstructive pulmonary disease	2.88e-05	0.000138	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.83e-05	0.000135	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.8e-05	0.000134	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.75e-05	0.000132	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.61e-05	0.000125	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—chronic obstructive pulmonary disease	2.58e-05	0.000123	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.54e-05	0.000121	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.5e-05	0.000119	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.46e-05	0.000118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.46e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.4e-05	0.000115	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	2.38e-05	0.000114	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.3e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.29e-05	0.000109	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.28e-05	0.000109	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.28e-05	0.000109	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—chronic obstructive pulmonary disease	2.25e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—chronic obstructive pulmonary disease	2.19e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.19e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.18e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.18e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.15e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.09e-05	9.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—chronic obstructive pulmonary disease	2.06e-05	9.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.05e-05	9.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—chronic obstructive pulmonary disease	2.02e-05	9.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2e-05	9.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.94e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.94e-05	9.25e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.91e-05	9.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.9e-05	9.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.84e-05	8.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.75e-05	8.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.75e-05	8.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.72e-05	8.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—chronic obstructive pulmonary disease	1.69e-05	8.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.61e-05	7.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.58e-05	7.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.57e-05	7.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—chronic obstructive pulmonary disease	1.56e-05	7.43e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	1.48e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.45e-05	6.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.42e-05	6.77e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	1.42e-05	6.76e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.34e-05	6.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.32e-05	6.32e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.29e-05	6.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.23e-05	5.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.19e-05	5.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.17e-05	5.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.09e-05	5.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	7.94e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	7.6e-06	3.63e-05	CbGpPWpGaD
